Heart Failure Reviews最新文献_第10页

Non-invasive myocardial work analysis in normal, at-risk for heart failure and heart failure patients during stress testing-a systematic review: a joint session with the Romanian Society of Cardiology (part III). 在压力测试中，正常、有心衰风险和心衰患者的无创心肌功分析——一项系统综述：罗马尼亚心脏病学会联合会议（第三部分）。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-02-04 DOI: 10.1007/s10741-025-10576-1

Dragoș Guz, Radu Filipescu, Andrew P Ambrosy, Matteo Pagnesi, Ovidiu Chioncel, Alexandre Mebazaa, Sean P Collins, Șerban Mihăileanu, Gad Cotter, Elena-Laura Antohi

{"title":"Non-invasive myocardial work analysis in normal, at-risk for heart failure and heart failure patients during stress testing-a systematic review: a joint session with the Romanian Society of Cardiology (part III).","authors":"Dragoș Guz, Radu Filipescu, Andrew P Ambrosy, Matteo Pagnesi, Ovidiu Chioncel, Alexandre Mebazaa, Sean P Collins, Șerban Mihăileanu, Gad Cotter, Elena-Laura Antohi","doi":"10.1007/s10741-025-10576-1","DOIUrl":"10.1007/s10741-025-10576-1","url":null,"abstract":"For over a decade, non-invasive myocardial work (MW) analysis, employing pressure-strain loops derived from strain deformation echocardiography, has been extensively studied across various left heart conditions. Recently, interest in MW variation during physical exercise or pharmacological stress testing has emerged. However, existing studies often involve heterogeneous populations, leaving the clinical significance of MW indices variation poorly understood. This review aims to systematically evaluate the literature on non-invasive MW parameter techniques and their changes during stress testing. MW analysis provides critical insights into cardiac function, aiding in the detection of underlying disease, such as coronary artery disease and heart failure. While numerous studies in diverse clinical settings have focused on MW assessment at rest, stress MW indices may more effectively predict treatment response and prognosis. Nevertheless, the current literature remains limited. Future research should prioritize addressing these knowledge gaps to fully harness the potential of MW analysis in clinical practice.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":"24"},"PeriodicalIF":5.3,"publicationDate":"2026-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118885","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heart failure with preserved ejection fraction: a systemic condition of comorbidities. 保留射血分数的心力衰竭：合并症的全身性状况。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-02-03 DOI: 10.1007/s10741-025-10586-z

Josephine Harrington, Ambarish Pandey

引用次数: 0

Hyponatraemia in heart failure: a mechanistic approach to contemporary management. 心力衰竭低钠血症：当代管理的一种机械方法。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-02-03 DOI: 10.1007/s10741-026-10595-6

Dominic M Alfonso, David A Aquino

{"title":"Hyponatraemia in heart failure: a mechanistic approach to contemporary management.","authors":"Dominic M Alfonso, David A Aquino","doi":"10.1007/s10741-026-10595-6","DOIUrl":"10.1007/s10741-026-10595-6","url":null,"abstract":"Hyponatraemia remains the most prevalent electrolyte disturbance in heart failure, complicating clinical management and correlating with adverse outcomes. While traditionally viewed as a biomarker of disease severity, mounting evidence suggests that hyponatraemia reflects specific pathophysiological mechanisms that demand targeted intervention alongside standard decongestion strategies. This mini review synthesises contemporary evidence to provide clinicians with an updated, mechanistically grounded approach to hyponatraemia in heart failure. We emphasise the critical distinction between dilutional hypervolaemic states driven by arginine vasopressin dysregulation and depletional hypovolaemic states arising from aggressive diuresis or sodium losses. Recent trials challenge longstanding practices: fluid restriction in stable chronic heart failure shows no quality-of-life benefit despite guideline recommendations, whilst emerging biomarkers such as early urine chloride offer promise in identifying diuretic resistance. We critically appraise the role of vasopressin antagonists, which correct sodium biochemically but lack mortality benefit, and explore oral urea as a pragmatic alternative supported by recent observational data. For acute severe presentations, we detail hypertonic saline protocols with strict correction limits and discuss proactive desmopressin strategies to prevent osmotic demyelination. Important knowledge gaps persist, including optimal diagnostic algorithms in diuretic-exposed patients, patient-centred outcome data for sodium-correcting therapies, and validation of safe-correction protocols. Overall, this review equips clinicians to integrate mechanistic understanding with evidence-based practice whilst identifying priorities for future investigation.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":"23"},"PeriodicalIF":5.3,"publicationDate":"2026-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146113029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing congestion in heart failure: tools are already available, but integration is key. 评估心力衰竭的充血：工具已经可用，但整合是关键。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-01-23 DOI: 10.1007/s10741-025-10592-1

Jolie Bruno, Sakura Minami, Tripti Rastogi, Andrew P Ambrosy, Alexandre Mebazaa, Nicolas Girerd

引用次数: 0

Correction to: Pharmacological prevention in cardio-oncology: from bench-to-bedside. 修正：心脏肿瘤学的药理学预防：从实验室到床边。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-01-20 DOI: 10.1007/s10741-025-10590-3

Ashot A Avagimyan, Nana Pogosova, Federica Fogacci, Olga Urazova, Zinaida Djndoyan, Liliya Mirzoyan, Gayane Avetisyan, Marco Bernardi, Luigi Spadafora, Davood Shafie, Francesco Perone, Marzieh Taheri, Arrigo Cicero, Giuseppe Biondi Zoccai, Riccardo Asteggiano, Rosalinda Madonna, Raffaele De Caterina, Nizal Sarrafzadegan

引用次数: 0

Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction. MUSIC-HFpEF的基本原理和设计：一项评估AAV1安全性和药效学效应的1b期先导试验。SERCA2A在保留射血分数的心力衰竭中的作用。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-01-17 DOI: 10.1007/s10741-025-10589-w

Marat Fudim, Satyam Sarma, James P MacNamara, Deborah D Ascheim, Veraprapas Kittipibul, Katheryn Doukellis, Andy Dhimitri, Robert Fitzhugh, Niharika Kamat, Kevin D Costa, Jeffrey Rudy, Janet Guerrero, Camie Chan, Ronald A Li, Anthony A Bavry, Manesh R Patel, Justin L Grodin, Benjamin D Levine, Roger J Hajjar

{"title":"Rationale and design of MUSIC-HFpEF: a phase 1b, pilot trial evaluating the safety and pharmacodynamic effects of AAV1.SERCA2A in heart failure with preserved ejection fraction.","authors":"Marat Fudim, Satyam Sarma, James P MacNamara, Deborah D Ascheim, Veraprapas Kittipibul, Katheryn Doukellis, Andy Dhimitri, Robert Fitzhugh, Niharika Kamat, Kevin D Costa, Jeffrey Rudy, Janet Guerrero, Camie Chan, Ronald A Li, Anthony A Bavry, Manesh R Patel, Justin L Grodin, Benjamin D Levine, Roger J Hajjar","doi":"10.1007/s10741-025-10589-w","DOIUrl":"10.1007/s10741-025-10589-w","url":null,"abstract":"Heart failure with preserved ejection fraction (HFpEF) has limited therapeutic options. Abnormal calcium handling through impaired sarcoplasmic/endoplasmic reticulum Ca2+ ATPase 2a (SERCA2a) activity contributes to diastolic dysfunction. AAV1.SERCA2A, an Adeno-Associated Virus Serotype 1 (AAV1) vector encoding SERCA2a, may improve myocardial relaxation in HFpEF. Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Preserved Ejection Fraction (MUSIC-HFpEF) is a Phase 1b, open-label, multicenter trial (NCT06061549) currently enrolling 10 patients with hemodynamically confirmed HFpEF. Patients receive a one-time intracoronary infusion of AAV1.SERCA2A. The primary objective is to assess safety and tolerability; secondary endpoints include effects on resting and exercise hemodynamics, echocardiographic measures of relaxation, N-terminal pro-B-type natriuretic peptide (NT-proBNP), and functional status. MUSIC-HFpEF is the first-in-human trial of SERCA2a gene therapy in HFpEF. Findings will inform the feasibility, safety, and potential clinical benefit of targeted gene therapy in this population. The study is enrolling participants and aims to clarify the safety profile and potential benefits of administering a single dose of AAV1.SERCA2A to individuals with HFpEF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":"19"},"PeriodicalIF":5.3,"publicationDate":"2026-01-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12812093/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145988946","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF. DIGIT-HF试验和Mihai georghiade的遗产：是时候重新考虑心脏糖苷作为HFrEF的有效治疗了。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-01-09 DOI: 10.1007/s10741-025-10593-0

Oliviana Geavlete, Andrew P Ambrosy, Jenna Skowronski, Magdy Abdelhamid, Nicolas Girerd, Tamas Alexy, Ovidiu Chioncel, Luca Monzo

{"title":"The DIGIT-HF trial and the Mihai Gheorghiade legacy: time to reconsider cardiac glycosides as effective therapy in HFrEF.","authors":"Oliviana Geavlete, Andrew P Ambrosy, Jenna Skowronski, Magdy Abdelhamid, Nicolas Girerd, Tamas Alexy, Ovidiu Chioncel, Luca Monzo","doi":"10.1007/s10741-025-10593-0","DOIUrl":"10.1007/s10741-025-10593-0","url":null,"abstract":"Cardiac glycosides have been used for more than two centuries in patients with heart failure with reduced ejection fraction (HFrEF), but their use has steadily declined in recent decades, largely due to safety concerns raised by observational studies and the availability of outcome-modifying therapies with more favorable safety profiles. Evidence from earlier randomized trials suggested that digoxin improves symptoms and reduces heart-failure hospitalizations without affecting survival, but these studies were conducted before the widespread adoption of contemporary guideline-directed medical therapy (GDMT). Digitoxin is a cardiac glycoside that differs from digoxin through its hepatic clearance and more stable pharmacokinetics, diminishing the impact of renal dysfunction and serum concentration fluctuations, thereby improving safety and facilitating long-term use in routine care. Here, we critically discuss in the context of available evidence the findings of the recently published DIGIT-HF (Digitoxin to Improve Outcomes in Patients with Advanced Chronic Heart Failure) trial, which for the first time evaluated the efficacy and safety of digitoxin in contemporary patients with HFrEF.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":"18"},"PeriodicalIF":5.3,"publicationDate":"2026-01-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145931627","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of the DAMSUN-HF trial: the role of an artificial intelligence stethoscope in detecting reduced ejection fraction in patients living in a low-resource region. DAMSUN-HF试验的评价：人工智能听诊器在检测低资源地区患者射血分数降低中的作用

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2026-01-05 DOI: 10.1007/s10741-025-10591-2

Dmitry Abramov, Baljash S Cheema, Kalliopi Keramida, Kaveh Hosseini, Marat Fudim, Abdul Mannan Khan Minhas

引用次数: 0

Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial. 评价马伐卡坦在症状性非阻塞性肥厚性心肌病中的作用：奥德赛- hcm试验

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2025-12-26 DOI: 10.1007/s10741-025-10578-z

Kaveh Hosseini, Sina Kazemian, Sivadasanpillai Harikrishnan, Aaron L Sverdlov, Baljash S Cheema, Zahra Hassan Abdulla Juma, Tor Biering-Sørensen, Avishay Grupper

{"title":"Evaluating the role of mavacamten in symptomatic non-obstructive hypertrophic cardiomyopathy: the ODYSSEY-HCM trial.","authors":"Kaveh Hosseini, Sina Kazemian, Sivadasanpillai Harikrishnan, Aaron L Sverdlov, Baljash S Cheema, Zahra Hassan Abdulla Juma, Tor Biering-Sørensen, Avishay Grupper","doi":"10.1007/s10741-025-10578-z","DOIUrl":"10.1007/s10741-025-10578-z","url":null,"abstract":"Non-obstructive hypertrophic cardiomyopathy (nHCM) is defined by exertional limitation without left ventricular outflow tract obstruction and lacks approved targeted therapies. ODYSSEY-HCM was a phase 3, randomized, double-blind, placebo-controlled trial that enrolled adults with symptomatic nHCM and left ventricular ejection fraction ≥ 60% to receive mavacamten, a selective cardiac myosin inhibitor, or placebo for 48 weeks with dose titration guided by serial echocardiography. The co-primary endpoints were the change in peak oxygen uptake and the 23-item Kansas City Cardiomyopathy Questionnaire clinical summary score. Mavacamten produced clear pharmacodynamic effects manifested by reductions in circulating markers of myocardial stress and imaging indices consistent with modest reverse remodelling, but it did not produce statistically significant improvement in the prespecified co-primary clinical endpoints at 48 weeks. Treatment was associated with an increased incidence of reversible reductions in ejection fraction necessitating protocol-mandated dose interruption, indicating a constrained therapeutic window in this cohort. Collectively, the data demonstrate target engagement without definitive patient-centered benefit over the study interval. Further evaluation is required, including randomized trials of agents with alternative pharmacokinetic and titration properties, studies with extended exposure, and phenotype-enriched enrollment, to determine whether biomarker and imaging responses can be translated into sustained improvements in functional capacity and health-related quality of life in patients with nHCM.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":"16"},"PeriodicalIF":5.3,"publicationDate":"2025-12-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145833893","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Monitoring heart involvement in treated and untreated transthyretin amyloidosis. 监测治疗和未治疗甲状腺转蛋白淀粉样变患者的心脏受累情况。

IF 5.3 2区医学

Heart Failure Reviews Pub Date : 2025-12-22 DOI: 10.1007/s10741-025-10588-x

Giulio Sinigiani, Paolo Milani, Laura De Michieli, Giuseppe Damiano Sanna, Stefano Perlini, Alberto Cipriani, Giovanni Palladini

{"title":"Monitoring heart involvement in treated and untreated transthyretin amyloidosis.","authors":"Giulio Sinigiani, Paolo Milani, Laura De Michieli, Giuseppe Damiano Sanna, Stefano Perlini, Alberto Cipriani, Giovanni Palladini","doi":"10.1007/s10741-025-10588-x","DOIUrl":"10.1007/s10741-025-10588-x","url":null,"abstract":"Transthyretin amyloidosis (ATTR) with heart involvement is a progressive, life-threatening condition characterized by amyloid fibril deposition in the myocardium, leading to heart failure, substantial morbidity, and increased mortality. Tafamidis, a transthyretin stabilizer, has been the first and for years the only available disease-modifying therapy, with proven survival benefit. However, a significant proportion of patients continue to experience clinical deterioration, underscoring the need for effective monitoring strategies to guide individual patient management and to serve as surrogate endpoints in clinical trials and in real-world clinical follow up. Current approaches to disease monitoring are largely adapted from heart failure management and include periodic assessment of clinical status, biomarkers, imaging, and functional capacity. Nevertheless, real-world data highlight important limitations, particularly in detecting early disease progression among treated patients. As novel therapies become increasingly available, early identification of suboptimal treatment response is critical to inform timely therapeutic decisions. Developing and validating a reproducible, easy framework for disease monitoring thus remain an urgent research priority. This narrative review summarizes current evidence on monitoring patients with ATTR and heart involvement, including both treated and untreated individuals. It also outlines future directions in this evolving field, emphasizing key knowledge gaps and opportunities for improvement.","PeriodicalId":12950,"journal":{"name":"Heart Failure Reviews","volume":"31 1","pages":"15"},"PeriodicalIF":5.3,"publicationDate":"2025-12-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12722399/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145804409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0